Evidence map›Paper›PMID 25490141›Full record

ArticleAntioxidants & redox signaling2015

Hemodynamic shear stress via ROS modulates PCSK9 expression in human vascular endothelial and smooth muscle cells and along the mouse aorta.

Zufeng Ding, Shijie Liu, Xianwei Wang, Xiaoyan Deng, Yubo Fan, Changqing Sun, Yannian Wang, Jawahar L Mehta

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in Antioxidants & redox signaling, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04338165 (Effect of Impact of PCSK9 Inhibitors on Coronary Microvascular Dysfunction in Patients With Atherosclerotic Cardiovascular Disease Proved by Myocardial Ischemia and Needing Coronarography), which is not on this map. Cited by 117 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
117citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04338165 phase2unknown statusstarted 2021, after this paper: background citation

Effect of Impact of PCSK9 Inhibitors on Coronary Microvascular Dysfunction in Patients With Atherosclerotic Cardiovascular Disease Proved by Myocardial Ischemia and Needing Coronarography : a Monocentric, Prospective, Randomized and Open-label Phase II Trial

Ran2021Enrolled66Registered outcomes6Posted comparisons0ConditionsAtherosclerotic Cardiovascular DiseaseArmsEvolocumab 140 MG/ML [Repatha]
Open the trial in the graph
3 · Its place in the literature

Who cites it

117 citing papers in PubMed, 1 synthesis or guideline pooled it, 223 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Observational
  10. International journal of molecular sciences · 2025
    Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. CRISPR-Cas9 Targeting PCSK9: A Promising Therapeutic Approach for Atherosclerosis.Journal of cardiovascular translational research · 2025
    Review
  19. Review
  20. Article

57 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Zufeng Ding1 Central Arkansas Veterans Healthcare System and the Departments of Medicine, and Physiology and Biophysics, University of Arkansas for Medical Sciences , Little Rock, Arkansas.
Shijie Liu
Xianwei Wang
Xiaoyan Deng
Yubo Fan
Changqing Sun
Yannian Wang
Jawahar L Mehta
Central Arkansas Veterans Healthcare System · USZhengzhou University · CNBeihang University · CN

Funding

PCSK9-A novel target for the treatment of myocardial ischemiaI01BX000282 · VA · CENTRAL ARKANSAS VETERANS HLTHCARE SYS · PI MEHTA, JAWAHAR L · 2009 to 2022
–
BLRD VA I01 BX000282
6 · The paper itself

Abstract

aimsTo investigate a possible link between hemodynamic shear stress, reactive oxygen species (ROS) generation, and proprotein convertase subtilisin/kexin type 9 (PCSK9) expression.

resultsUsing a parallel-plate flow chamber, we observed that PCSK9 expression in vascular smooth muscle cells (SMCs) and endothelial cells (ECs) reached maximal value at low shear stress (3-6 dynes/cm(2)), and then began to decline with an increase in shear stress. PCSK9 expression increased when cells were treated with lipopolysaccharide. PCSK9 expression was always greater in SMCs than in ECs. ROS generation followed the same pattern as PCSK9 expression. Aortic branching and aorta-iliac bifurcation regions of mouse aorta that express low shear stress were also found to have greater PCSK9 expression (vs. other regions). To determine a relationship between ROS and PCSK9 expression, ECs and SMCs were treated with ROS inhibitors diphenylene-iodonium chloride and apocynin, and both markedly reduced PCSK9 expression. Relationship between PCSK9 and ROS was further studied in p47(phox) and gp91(phox) knockout mice; both mice strains revealed low PCSK9 levels in serum and mRNA levels in aorta-iliac bifurcation regions (vs. wild-type mice). Other studies showed that ROS and NF-κB activation plays a bridging role in PCSK9 expression via lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1). INNOVATION: Low shear stress induces PCSK9 expression, which is mediated by NADPH oxidase-dependent ROS production.

conclusionsThis study provides evidence that low shear stress enhances PCSK9 expression in concert with ROS generation in vascular ECs and SMCs. ROS seem to regulate PCSK9 expression. We propose that PCSK9-ROS interaction may be important in the development of atherosclerosis in arterial channels with low shear stress.

Indexed as

HemodynamicsStress, MechanicalAcetophenonesAnimalsAntioxidantsAortaEndothelium, VascularHumansInflammationLipopolysaccharidesMembrane GlycoproteinsMice, Inbred C57BLMice, TransgenicMyocytes, Smooth MuscleNADPH Oxidase 2NADPH OxidasesAcetophenonesacetovanilloneAntioxidantsCybb protein, mousediphenyleneiodoniumlipopolysaccharide ALipopolysaccharidesMembrane GlycoproteinsNADPH Oxidase 2NADPH Oxidasesneutrophil cytosolic factor 1NF-kappa BOlr1 protein, mouseOnium CompoundsPCSK9 protein, humanPcsk9 protein, mouseProprotein Convertase 9Proprotein ConvertasesReactive Oxygen SpeciesScavenger Receptors, Class ESerine EndopeptidasesVascular Cell Adhesion Molecule-1

Identifiers

PMID25490141
PMCPMC4361218
OpenAlexW2021283737

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.